Every 8-K that Dogwood Therapeutics, Inc. (DWTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DWTX filings page.
Dogwood Therapeutics, Inc. reported second quarter 2026 results with no revenue and a focus on advancing its non-opioid pain pipeline. The Halneuron® Phase 2b trial in chemotherapy-induced neuropathic pain is on track for top-line data in fall 2026, with 217 patients enrolled and plans to enroll over 220 patients to provide more than 80% statistical power.
For the quarter ended June 30, 2026, research and development expenses were $3.25 million and general and administrative expenses were $1.63 million. Dogwood recorded a non-cash IPR&D impairment charge of $9.19 million, leading to a net loss attributable to common stockholders of $11.53 million, or $0.34 per share. Cash was $9.61 million as of June 30, 2026.
Strategically, Dogwood highlighted a worldwide development and commercialization partnership for legacy antiviral assets with potential value of up to $100 million for the company and its CVR holders, the start of a Phase 2b long-term extension study of Halneuron®, and a fully National Cancer Institute–funded forthcoming SP16 IV Phase 1b trial.
Dogwood Therapeutics, Inc. held its annual stockholder meeting, where investors approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. Stockholders also elected seven directors, ratified Forvis Mazars, LLP as auditor for 2026, and endorsed executive pay.
Holders of 31,791,500 common shares, representing 95.17% of the voting power as of the record date, were present in person or by proxy, providing a strong quorum. Stockholders supported holding advisory votes on executive compensation every year, and the Board agreed to include this annual vote in future proxy materials.
Dogwood Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger finances. The company recorded no revenue, with research and development expenses of $2.7 million and general and administrative expenses of $2.4 million, both modestly higher than a year earlier.
Net loss attributable to common stockholders narrowed to $5.0 million, or $0.15 per share, from $12.2 million, or $8.45 per share, in the first quarter of 2025. Cash and cash equivalents increased to $13.2 million as of March 31, 2026.
Operationally, Halneuron® remains on track for Phase 2b top-line data in chemotherapy-induced neuropathy in fall 2026, and SP16 advanced with FDA acceptance of its investigational new drug application and planned Phase 1b development. Dogwood also announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million for the company and its current and former shareholders.
Dogwood Therapeutics filed a Form 8-K to furnish a shareholder letter providing a first quarter 2026 corporate update. The company is a development-stage biopharmaceutical business focused on new non-opioid medicines to treat pain and neuropathic disorders, especially cancer- and chemotherapy-induced neuropathic pain.
Dogwood highlights two first-in-class candidates, Halneuron and SP16 IV. Halneuron is in Phase 2b development for pain conditions including chemotherapy-induced neuropathic pain and has FDA fast track designation for CINP. SP16 IV, an LRP1 agonist, has shown preclinical anti-inflammatory and potential nerve-repair effects, with a forthcoming Phase 1b CINP trial fully funded by the National Cancer Institute.
Dogwood Therapeutics reported fourth quarter and full year 2025 results, highlighting increased investment in its pain and neuropathy pipeline and a longer cash runway. For Q4 2025, research and development expenses were $2.3 million, roughly flat year over year, while general and administrative expenses fell to $1.5 million from $5.2 million, mainly as prior transaction costs rolled off. Quarterly net loss attributable to common stockholders narrowed to $3.8 million, or $0.26 per share, from $8.2 million, or $6.29 per share.
For full year 2025, research and development expenses rose to $21.8 million from $3.5 million, driven by $12.0 million of acquired in-process R&D for SP16, higher Halneuron® Phase 2b clinical trial costs, and manufacturing and personnel spending. General and administrative expenses decreased to $6.1 million from $8.7 million, reflecting lower nonrecurring transaction and public company costs, partially offset by higher salaries, legal and professional fees, and taxes. Net loss attributable to common stockholders grew to $35.5 million, or $7.13 per share, from $12.9 million, or $12.52 per share.
As of December 31, 2025, cash and cash equivalents were $6.5 million. The company expects this balance, together with $11.4 million of net proceeds received in January 2026, to fund operations through the Halneuron® Phase 2b final data readout and into the fourth quarter of 2026. Dogwood’s pipeline centers on Halneuron®, a fast track–designated, non-opioid NaV 1.7 analgesic in Phase 2b for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist for neuropathy with a forthcoming, National Cancer Institute–funded Phase 1b CINP trial.
Dogwood Therapeutics, Inc. reported that shareholders approved the potential exercise of an unregistered common stock warrant to purchase up to 4,386,037 shares of common stock under a January 11, 2026 Securities Purchase Agreement and Nasdaq Listing Rule 5635(d).
At the Special Meeting, 29,310,309 common shares were represented, equal to 88.03% of the voting power as of the February 12, 2026 record date, establishing a quorum. The warrant exercise proposal passed with 29,286,786 votes for, 19,057 against and 4,466 abstentions. Shareholders also approved a proposal permitting adjournment of the Special Meeting if necessary, with 29,283,790 votes for, 21,571 against and 4,948 abstentions.
Dogwood Therapeutics, Inc. submitted a current report noting that it has posted a shareholder letter to its website, dated January 20, 2026. The letter provides a corporate update for shareholders and is included as Exhibit 99.1 to the report. The company specifies that this shareholder letter is being furnished for information purposes under securities regulations and is not being treated as filed or incorporated into other securities law filings.
Dogwood Therapeutics, Inc. completed a combined registered direct offering and concurrent private placement, raising approximately $12.5 million in gross proceeds.
It sold 2,338,948 shares of common stock in the registered deal, plus pre-funded warrants for 2,047,089 shares and common stock warrants for 4,386,037 shares, generally priced around $2.85 per share and accompanying warrant. The common stock warrants become exercisable for five and one-half years after stockholder approval at $3.28 per share, while the pre-funded warrants are immediately exercisable at a nominal price. Dogwood also terminated its prior at-the-market equity program with Northland, under which it had sold only $89,792 of stock out of an authorized $8,558,712.
Dogwood Therapeutics, Inc. reported that stockholders approved several key proposals at a special meeting held on November 21, 2025. The Second Amended and Restated Equity Incentive Plan was approved, increasing the shares of common stock reserved under the prior plan by 2,781,665 shares to a total of 2,972,787 shares. Stockholders also approved the potential issuance of common stock upon conversion of the Company’s Series A, Series A-1, and Series A-2 Non-Voting Convertible Preferred Stock. Following approval of the Series A conversion, the Company’s business combination with Sealbond Limited under the Share Exchange Agreement dated October 7, 2024 is complete. A quorum was present, with 820,239 shares representing 35.76% of voting power as of the record date, and all matters received sufficient votes, including for Nasdaq Listing Rule 5635 purposes.
Dogwood Therapeutics (DWTX) furnished an update on its financial performance. On November 6, 2025, the company announced results for the third quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The information is expressly furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings.
Dogwood Therapeutics, Inc. filed a current report to let the market know it has posted an investor presentation on its website. The presentation, dated October 9, 2025, may be used in discussions with investors, analysts, collaborators, vendors and other third parties.
The presentation is furnished as Exhibit 99.1 to the report and is provided under a disclosure category that is not treated as formally filed with the SEC. This means it is available for information purposes but is not automatically incorporated into Dogwood’s Securities Act filings.
Dogwood Therapeutics entered into an Exclusive Licensing Agreement with Serpin Pharma and Rejuvenation Labs granting Dogwood a royalty-free, sublicensable global license to develop Serpin's intravenous formulation of SP16, a first-in-class LRP1 agonist with reported anti-inflammatory and neural repair activity that may treat chemotherapy-induced peripheral neuropathy. As consideration, Dogwood agreed to issue 191,017 shares of common stock and 89.5939 shares of Series A-2 Non-Voting Convertible Preferred Stock to Serpin Pharma and the same amounts to Rejuvenation Labs. Tungsten received 10.8694 shares of Series A-2 Preferred Stock as advisor compensation. Related registration, support and voting agreements require Serpin, Tungsten-affiliated holders, and Sealbond to vote their shares in favor of proposals concerning potential issuances related to Series A, Series A-1 and Series A-2 conversions, certain equity plan matters, and possible adjournment of the meeting.